Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured

FDA review of INOVIO's INO-3107 for RRP targets Oct 2026 approval; positive Phase 3 VGX-3100 results in China reported.

INOVIO's FDA review for INO-3107, a treatment for Recurrent Respiratory Papillomatosis (RRP), is progressing with a target approval date of October 30, 2026. The company is preparing for commercial launch and has engaged partners for sales and distri...